Scholarlink

<p>Prognosis for patients with unresectable intrahepatic cholangiocarcinoma (iCC) remains poor despite advances in systemic therapy. This review delineates the indications and outcomes for hepatic artery infusion pump (HAIP) therapy in patients with liver-limited iCC based on retrospective reviews and single-arm studies. Early results have shown favorable outcomes when incorporating HAIP in the management strategy, including impressive 3-year survival rates ranging from 31 to 40%. Randomized controlled trials will be vital in defining the role of HAIP in current treatment regimens (e.g. first-line vs. second-line). As data continue to accumulate, we emphasize the importance of patient selection within the context of comprehensive multidisciplinary evaluation. Finally, we discuss promising new therapeutic strategies for HAIP as applied to patients with cholangiocarcinoma, including the introduction of novel agents, and approaches to mitigating dose-limiting toxicities, and thereby maximizing therapeutic benefit.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hepatic Artery Infusion Pump Therapy for Intrahepatic Cholangiocarcinoma: Indications and Outcomes

  • 期刊论文

  • 发表日期：

    2025年12月22日

查看全文
  • Jason Ho,
  • Sophia Xiao,
  • Jonathan M. Hernandez

摘要

Prognosis for patients with unresectable intrahepatic cholangiocarcinoma (iCC) remains poor despite advances in systemic therapy. This review delineates the indications and outcomes for hepatic artery infusion pump (HAIP) therapy in patients with liver-limited iCC based on retrospective reviews and single-arm studies. Early results have shown favorable outcomes when incorporating HAIP in the management strategy, including impressive 3-year survival rates ranging from 31 to 40%. Randomized controlled trials will be vital in defining the role of HAIP in current treatment regimens (e.g. first-line vs. second-line). As data continue to accumulate, we emphasize the importance of patient selection within the context of comprehensive multidisciplinary evaluation. Finally, we discuss promising new therapeutic strategies for HAIP as applied to patients with cholangiocarcinoma, including the introduction of novel agents, and approaches to mitigating dose-limiting toxicities, and thereby maximizing therapeutic benefit.